Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer
Article Category: Review
Published Online: Sep 24, 2019
Page range: 285 - 292
Received: Jan 03, 2019
Accepted: Jul 20, 2019
DOI: https://doi.org/10.2478/raon-2019-0038
© 2019 Tanja Ovcaricek, Iztok Takac, Erika Matos, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Background
The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine therapy. Adjuvant systemic therapy reduces the risk of recurrence and death from BC. Whether an individual patient will benefit from adjuvant chemotherapy is an important clinical decision. Decisions that rely solely on clinical-pathological factors can often lead to overtreatment. Multigene signatures represent an important progress in optimal selection of high risk patients that might benefit from the addition of chemotherapy to adjuvant endocrine therapy.
Conclusions
Several signatures are already commercially available and also accepted by international guidelines. Oncotype DX and MammaPrint have been most extensively validated and supported by level IA evidence.